FDA Approves Darzalex Faspro in Combination with Bortezomib, Lenalidomide, and Dexamethasone (VRd) for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approves-darzalex-plus-vrd-for-ndmm)